Zevra Therapeutics, Inc. $ZVRA Shares Acquired by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. boosted its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 487.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 117,576 shares of the company’s stock after purchasing an additional 97,575 shares during the quarter. Cantor Fitzgerald L. P. owned about 0.21% of Zevra Therapeutics worth $1,118,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares during the last quarter. Strs Ohio acquired a new stake in shares of Zevra Therapeutics during the 1st quarter worth $125,000. Geode Capital Management LLC increased its holdings in shares of Zevra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock worth $10,948,000 after buying an additional 9,275 shares during the last quarter. Creative Planning purchased a new position in shares of Zevra Therapeutics in the 2nd quarter worth $92,000. Finally, Legal & General Group Plc boosted its holdings in Zevra Therapeutics by 26.8% in the second quarter. Legal & General Group Plc now owns 935,677 shares of the company’s stock valued at $8,243,000 after acquiring an additional 197,940 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Insider Activity

In other news, insider Adrian W. Quartel sold 4,533 shares of the company’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $8.83, for a total value of $40,026.39. Following the completion of the transaction, the insider directly owned 9,723 shares in the company, valued at approximately $85,854.09. This represents a 31.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joshua Schafer sold 10,500 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total transaction of $96,495.00. Following the completion of the transaction, the insider directly owned 62,278 shares of the company’s stock, valued at approximately $572,334.82. The trade was a 14.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 114,158 shares of company stock valued at $1,062,878 over the last ninety days. 2.40% of the stock is owned by company insiders.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA opened at $9.98 on Monday. The company has a market cap of $585.93 million, a P/E ratio of 7.50 and a beta of 0.91. The company has a debt-to-equity ratio of 0.40, a quick ratio of 5.63 and a current ratio of 5.68. Zevra Therapeutics, Inc. has a one year low of $6.19 and a one year high of $13.16. The business’s 50-day simple moving average is $8.93 and its 200 day simple moving average is $9.09.

Wall Street Analyst Weigh In

Several brokerages have commented on ZVRA. Wall Street Zen lowered Zevra Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. HC Wainwright set a $26.00 target price on Zevra Therapeutics in a report on Tuesday, December 30th. Guggenheim set a $23.00 price target on shares of Zevra Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 10th. Finally, Weiss Ratings upgraded shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research note on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.